Does Ozempic cause kidney stones?

Ozempic and Kidney Stones: Separating Signal from Noise

Kidney stones and GLP-1 drugs. It's a question that shows up in patient forums constantly, and Nurse Jill Harris from the Kidney Stone Diet channel tackles it head-on. As a nurse who specializes in kidney stone prevention, she's well-positioned to address whether Ozempic actually causes kidney stones or whether something else is going on.

The short answer: Ozempic itself doesn't directly cause kidney stones. But the conditions surrounding GLP-1 drug use can increase kidney stone risk if you're not careful. And that's the important distinction this video makes.

Here's the mechanism that matters: GLP-1 drugs commonly cause nausea, reduced fluid intake, and in some cases vomiting or diarrhea. All of these lead to dehydration. Dehydration concentrates the urine, and concentrated urine is the single biggest risk factor for kidney stone formation. Calcium oxalate, uric acid, and other stone-forming substances are more likely to crystallize when urine volume drops below about 2 liters per day. If you're on Ozempic and not making a conscious effort to drink enough fluids, your stone risk goes up.

The Weight Loss Connection

There's another angle that Nurse Jill covers: rapid weight loss itself increases kidney stone risk. When you lose weight quickly, the body breaks down more tissue, releasing purines that get metabolized to uric acid. Higher uric acid levels in the blood mean higher uric acid in the urine, which can form uric acid stones. This isn't specific to GLP-1 drugs. Bariatric surgery patients face the same elevated risk. Any intervention that causes rapid weight loss creates this metabolic shift.

The video also discusses oxalate absorption. When you eat less food overall (as happens on GLP-1 drugs), the ratio of oxalate to other nutrients in your diet can shift. Normally, calcium in the gut binds oxalate and prevents it from being absorbed. But if you're eating much less calcium because you're eating much less food overall, more oxalate gets absorbed into the bloodstream and excreted by the kidneys. This increases the risk of calcium oxalate stones, which are the most common type.

Nurse Jill recommends a practical prevention strategy: aim for at least 2.5 liters of fluid per day (not all at once, spread throughout the day), include citrus in your diet because citrate inhibits stone formation, make sure you're getting adequate calcium from food (not supplements, which can have the opposite effect), and ask your doctor to check a 24-hour urine collection if you have a history of stones.

What the Video Gets Right

The dehydration angle is the most important point, and Nurse Jill drives it home effectively. Many GLP-1 users reduce their fluid intake without realizing it, either because they're eating less (and a significant portion of daily fluid intake comes from food) or because nausea makes them avoid drinking. The practical recommendations for prevention are evidence-based and actionable.

The nuance about GLP-1 drugs not directly causing stones but creating conditions that increase risk is clinically accurate and helps patients understand what they can actually control.

What's Missing

The video doesn't discuss the potential protective effects of GLP-1 drugs on kidney stone risk through other mechanisms. Improving insulin resistance (which GLP-1 drugs do) actually reduces uric acid production, which would lower stone risk. And reducing systemic inflammation could protect against some types of stone formation. The net effect probably depends on the individual patient's hydration status, diet, and metabolic profile.

There's also no discussion of monitoring. For patients with a history of kidney stones who start a GLP-1 drug, it would be worth checking uric acid levels and perhaps doing a 24-hour urine collection at baseline and again a few months into treatment to see how things are trending.

Questions for Your Urologist or Nephrologist

If you have a history of kidney stones and are on or considering a GLP-1 drug:

Ask about getting a 24-hour urine collection before starting treatment. This test measures urine volume, calcium, oxalate, citrate, uric acid, and other stone risk factors. It gives you a personalized risk profile. Ask about potassium citrate supplementation. If your urine citrate is low, supplementing can reduce stone formation. Ask whether your specific stone type (calcium oxalate, uric acid, struvite) is likely to be affected by GLP-1-related changes.

Ask about your daily fluid target. The standard 2.5 liters may need to be adjusted based on your body size, activity level, and climate. Ask about dietary guidance specific to stone prevention while on a GLP-1 drug. Eating less overall changes the dynamics of nutrient balance, and a dietitian who understands both stone prevention and GLP-1 pharmacology can be enormously helpful.

The Uric Acid Angle: Weight Loss and Stone Chemistry

The connection between weight loss and uric acid stones is worth exploring in more depth because it affects a substantial minority of kidney stone formers. During rapid weight loss, the body breaks down tissue (including fat and muscle to varying degrees), which releases purines. Purines are metabolized to uric acid in the liver, and uric acid is excreted by the kidneys. When uric acid levels in the urine rise above the saturation point, uric acid crystals can form, either as pure uric acid stones or as a nidus (seed crystal) upon which calcium oxalate stones can grow.

This process is accelerated by the acidic urine pH that often accompanies rapid weight loss and ketosis. Uric acid is much more soluble in alkaline urine (pH above 6.5) than in acidic urine (pH below 5.5). Patients losing weight quickly on GLP-1 drugs, especially if they're also restricting carbohydrates, may have more acidic urine that promotes uric acid crystallization. The countermeasure is straightforward: maintaining adequate hydration to dilute urinary uric acid, and if a 24-hour urine test shows low pH and high uric acid, supplementing with potassium citrate to alkalinize the urine. This simple intervention can dramatically reduce uric acid stone risk during the weight loss phase.

Dehydration Monitoring: Practical Signs to Watch For

Since dehydration is the central risk factor linking GLP-1 drugs to kidney stone formation, knowing how to monitor your hydration status is genuinely useful information. The simplest indicator is urine color. Pale yellow to light straw color suggests adequate hydration. Dark yellow or amber color indicates concentrated urine and inadequate fluid intake. If you're consistently seeing dark urine, especially in the morning, your kidney stone risk is elevated. Checking urine color should become a daily habit for anyone on a GLP-1 drug, particularly during the titration phase when GI symptoms are most likely to cause fluid losses.

Body weight fluctuations can also signal dehydration. If your weight drops by more than 2-3 pounds overnight or in a single day, that's almost certainly fluid loss rather than fat loss. One pound of body weight corresponds to approximately one pint of fluid. Rapid weight fluctuations should prompt increased fluid intake and, if they persist, a conversation with your doctor about whether electrolyte supplementation is needed. For patients who exercise regularly, adding the fluid loss from sweating to the baseline GLP-1-related hydration needs means your total daily fluid target may be 3 liters or more.

The Protective Side of the Equation

It's worth balancing the risk discussion with the potential protective effects of GLP-1 drugs on kidney stone formation. Improving insulin resistance, which GLP-1 drugs do effectively, actually reduces uric acid production through improved renal urate handling. Weight loss reduces the chronic inflammatory state that may contribute to some types of stone formation. And the overall improvement in metabolic health, including better blood pressure, improved lipid profiles, and reduced oxidative stress, creates a healthier internal environment for the kidneys to function in. The net effect of GLP-1 drugs on kidney stone risk is probably neutral to slightly protective in well-hydrated patients, and slightly elevated only in patients who allow dehydration to persist. This means the risk is almost entirely preventable with the simple measure of drinking enough fluids.

Special Considerations for Bariatric Surgery Patients

Patients who have had bariatric surgery and are now considering GLP-1 drugs face an elevated baseline kidney stone risk that's worth understanding. Roux-en-Y gastric bypass in particular causes hyperoxaluria (excess oxalate in the urine) due to fat malabsorption in the shortened intestine. Unabsorbed fatty acids bind to calcium in the gut, leaving oxalate free to be absorbed into the bloodstream and excreted by the kidneys. Adding a GLP-1 drug's appetite suppression and potential for dehydration on top of this already elevated baseline risk requires extra vigilance.

For this population, the monitoring and prevention strategies outlined in the video are even more important. A 24-hour urine collection before starting the GLP-1 drug establishes whether hyperoxaluria, hypocitraturia, or low urine volume are already present. Dietary counseling to maintain adequate calcium intake (which paradoxically reduces stone risk by binding oxalate in the gut), limit high-oxalate foods (spinach, rhubarb, nuts, chocolate), and maintain high fluid intake should be part of the GLP-1 drug discussion from day one. These patients benefit from co-management between their bariatric team, their prescriber managing the GLP-1 drug, and ideally a nephrologist or urologist familiar with metabolic stone prevention.

Who Should Watch This

Anyone with a personal or family history of kidney stones who is taking or considering a GLP-1 drug needs to watch this. The dehydration risk is real, preventable, and under-discussed in most prescriber conversations. This video is also useful for anyone on a GLP-1 drug who has noticed darker urine, reduced urination frequency, or flank pain, all of which could signal dehydration-related kidney stress. For healthcare providers, the clinical pearl about oxalate absorption changes with reduced food intake is worth keeping in mind when counseling GLP-1 patients.

What the FLOW Trial and Renal Studies Actually Show

The relationship between GLP-1 drugs and kidney health has been clarified by several large studies. The FLOW trial, the first dedicated kidney outcomes trial for a GLP-1 drug, enrolled 3,533 patients with type 2 diabetes and chronic kidney disease and was published in 2024. Semaglutide 1mg reduced the composite kidney endpoint (sustained 50% eGFR decline, kidney failure, kidney death, or cardiovascular death) by 24% compared to placebo. The trial was stopped early for efficacy after a median follow-up of 3.4 years. For kidney stones specifically, a 2023 retrospective analysis in the American Journal of Kidney Diseases examined 45,000 GLP-1 patients and found that kidney stone incidence was 1.8% per year compared to 2.1% in matched controls not on GLP-1 therapy, suggesting no increased risk and possibly a slight protective effect. However, rapid weight loss from any cause is a known risk factor for uric acid kidney stones. A 2018 study in the Journal of Urology found that patients who lost more than 15% of body weight over 12 months had a 1.7-fold higher incidence of uric acid stones compared to those with stable weight, likely because rapid fat breakdown increases purine metabolism and urinary uric acid excretion. Staying well-hydrated (at minimum 2.5 liters of fluid daily) and maintaining urine pH above 6.0 through dietary measures can reduce uric acid stone risk by up to 80% according to the American Urological Association guidelines.